Skip to content
OpenCapital
Get started

Lifecore Biomedical, Inc. LFCR Temporary equity, directors, stock outstanding threshold

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M—
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M—
CapEx$1.1M-46.7%
Free cash flow$3.6M—

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%—
FCF margin-36.4%—

Returns & leverage

See full
Return on equity-612.1%—
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept lfcr:TemporaryEquityDirectorsStockOutstandingThreshold.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s temporary equity, directors, stock outstanding threshold.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s temporary equity, directors, stock outstanding threshold?
Lifecore Biomedical, Inc. (LFCR) reported temporary equity, directors, stock outstanding threshold of 30% in Q1 2026.